



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---|--|---|
| <p>(51) International Patent Classification ⁷ : C12N 5/04, 15/05, 15/09, 15/31, 15/63, 15/82, A01H 4/00, 3/04, 5/00, 5/10, C12P 21/02</p> | A1 | <p>(11) International Publication Number: WO 00/26344</p> <p>(43) International Publication Date: 11 May 2000 (11.05.00)</p> |
| <p>(21) International Application Number: PCT/US99/25561</p> <p>(22) International Filing Date: 29 October 1999 (29.10.99)</p> <p>(30) Priority Data: 60/106,373 30 October 1998 (30.10.98) US 60/106,537 2 November 1998 (02.11.98) US</p> <p>(71) Applicants: INTERLINK BIOTECHNOLOGIES LLC [US/US]; 221 Commons Way, Building #2, Princeton, NJ 08540 (US). UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION [US/US]; 201 Kinkead Hall, Lexington, KY 40506-0057 (US).</p> <p>(72) Inventors: EVERETT, Nicholas, P.; 604 Apple Tree Lane, Meadow Vista, CA 95722 (US). LI, Qingshun; 2268 Cam- breling Drive, Lexington, KY 40515 (US). LAWRENCE, Christopher; 625 Sheridan Drive, Lexington, KY 40503 (US). DAVIES, Maelor, H.; 2137 Leafland Place, Lexing- ton, KY 40515 (US).</p> <p>(74) Agents: GARBELL, Jason, I. et al.; Lerner, David, Littenberg, Krumholz & Mentlik LLP, 600 South Avenue West, West- field, NJ 07090 (US).</p> | <p>(81) Designated States: AT, AU, BR, CA, JP, MX, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> | |
| <p>(54) Title: PEPTIDES WITH ENHANCED STABILITY TO PROTEASE DEGRADATION</p> | | |
| <p>(57) Abstract</p> <p>Disclosed are peptides that have enhanced stability against plant proteases and are useful in the control of plant diseases. The peptides also have the ability to protect other peptides, polypeptides or proteins from degradation by proteases of plant, fungal, viral, bacterial, insect or other origin. DNA encoding the peptides of the present invention can be co-expressed with other DNA encoding exogenous peptides in transgenic plants as a method for protecting foreign peptides from degradation by proteases. Also disclosed are nucleic acid sequences, microorganisms, plants, and compositions useful for the treatment of plant diseases.</p> | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|-----------|--------------------------|-----------|--|-----------|--|-----------|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MX | Mexico | UG | Uganda |
| BY | Belarus | IS | Iceland | MW | Malawi | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakistan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

PEPTIDES WITH ENHANCED
STABILITY TO PROTEASE DEGRADATION

The present application claims the benefit of United States Provisional Patent Application Nos. 60/106,373 and 5 60/106,573, filed October 30, 1998 and November 2, 1998, respectively, the disclosures of which are hereby incorporated by reference herein.

FIELD OF THE INVENTION

The present invention relates to antimicrobial 10 peptides which are resistant to proteases and which have the ability to reduce the extent of protease degradation of peptides, polypeptides and proteins in plants.

BACKGROUND OF THE INVENTION

Antimicrobial peptides are produced by a wide range 15 of organisms as part of their defense against infection. See Hancock & Lehrer, 1998, TIBTECH, 16:82-88; Everett, 1994, Chpt. 20 In: Natural and Engineered Pest Management Agents, eds. Hedin, Menn & Hollingworth, ACS Symposium Series 551, pp. 278-91. Examples of such peptides include cecropins, attacins 20 and diptericins which are involved in cell-free immunity in insects, the apidaecins from honeybees, the defensins from mammalian phagocytes, and the magainins from frog skin. Plants also produce certain classes of antimicrobial peptides which are thought to play a role in resistance to microbial 25 plant pathogens. See Broekaert et al., 1997, Critical Reviews in Plant Sciences, 16:297-323.

Plants have been genetically engineered to produce antimicrobial peptides, both natural and synthetic to increase resistance to disease. See Jaynes et al., 1987, BioEssays, 30 6:263-70; Hancock and Lehrer, 1998, TIBTECH, 16:82-88. Unfortunately, this approach has met with very limited success. Either the amount of peptide produced by the transgenic plant is too small and/or the plants are no less susceptible to infection by plant pathogens. See Hancock and 35 Lehrer, 1998, TIBTECH, 16:82-88. A major limitation to the expression of foreign peptides in transgenic plants is due to

the susceptibility of the foreign peptides to rapid degradation by proteases. For example, transgenic potato cultivars which express a gene encoding the antimicrobial peptide cecropin B at levels up to 0.6% of total mRNA produce
5 no detectable cecropin B peptide and no improvement in resistance to potato soft rot. See Sjefke et al., 1995, American Potato Journal, 72:437-45. Similar studies in tobacco have demonstrated that expression of cecropin B genes also does not result in detectable cecropin B peptide levels
10 and resistance to bacterial infections. See Florack et al., 1995, Transgenic Research 4:132-41. Studies have also shown that cecropin B and antimicrobial peptides related to magainins are rapidly degraded by proteases in the intercellular fluid of plant leaves. See Mills et al., 1994,
15 Plant Science, 104:17-22 and Everett, 1994, Chpt. 20 In: Natural and Engineered Pest Management Agents, eds. Hedin, Menn & Hollingworth, ACS Symposium Series 551, pp. 278-91.

One proposed solution to the problem of peptide instability due to protease degradation has been to identify
20 the protease-sensitive sites within a particular peptide and to design amino acid substitutions that increase the stability of peptides to plant proteases while retaining the antimicrobial activity of the peptides. This approach resulted in a synthetic magainin derivative having the amino
25 acid sequence Met-Gly-Ile-Gly-Lys-Phe-Leu-Arg-Glu-Ala-Gly-Lys-Phe-Gly-Lys-Ala-Phe-Val-Gly-Glu-Ile-Met-Lys-Pro that had enhanced stability against proteases found in the intercellular fluid of plant tissues and was therefore an improved candidate for use in or on plants. See Everett,
30 1994, Chpt. 20 In: Natural and Engineered Pest Management Agents, eds. Hedin, Menn & Hollingworth, ACS Symposium Series 551, pp. 278-91; U.S. Patents Nos. 5,424,395 and 5,519,115.

Another proposed solution to the problem of peptide instability has been to produce the reverse- or retro-analogs
35 of natural antimicrobial peptides or their synthetic derivatives. See U.S. Patent No. 5,519,115, and Merrifield et

al., 1995, PNAS, 92:3449-53. Such reverse-peptides retain the same general three-dimensional structure (e.g., alpha-helix) as the parent peptide except for the conformation around internal protease-sensitive sites and the characteristics of the N- and C-termini. Reverse peptides are purported not only to retain the biological activity of the non-reversed "normal" peptide but may possess enhanced properties, including increased antibacterial activity and reduced hemolysis. See Iwahori et al., 1997, Biol. Pharm. Bull. 20:267-70.

Indolicidin, having the amino acid sequence Ile-Leu-Pro-Trp-Lys-Trp-Pro-Trp-Trp-Pro-Trp-Arg-Arg, is a potent antimicrobial tridecapeptide. It was originally purified from cytoplasmic granules of bovine neutrophils. See Selsted et al., 1993, J. Biol. Chem., 267:4292-95. It is a member of a class of proline-rich peptides that have been recovered from the leukocytes of different mammals, a marine invertebrate and insect haemolymph. See Hancock and Lehrer, 1998, TIBTECH, 16:82-88. The antimicrobial potencies of natural and synthetic indolicidin are identical. See Van Abel et al., 1995, Int. J. Protein Res. 45:401-09. The mode of antibacterial action of indolicidin has been reported to be based on the disruption of the cytoplasmic membrane by channel formation. See Falla et al., 1996, J. Biol. Chem. 32:19298-303. More recently, it has been suggested that membrane permeabilization is likely to occur due to deformation of the membrane surface rather than formation of transmembrane channels by indolicidin and its analogs. See Subbalakshmi et al., 1998, J. Biosci., 23:9-13.

Numerous analogs of indolicidin have been synthesized and tested in attempts to evaluate the requirements for antimicrobial and hemolytic activities, and to increase activity. Subbalakshmi et al. (FEBS Letters 395:48-52 (1996)) reports that peptides in which proline was replaced by alanine and tryptophan was replaced by phenylalanine exhibit antibacterial activities comparable to

that of indolicidin. The replacement of tryptophan by phenylalanine, however resulted in a loss of hemolytic activity. Falla and Hancock (Antimicrobial Agents and Chemotherapy, 41:771-75 (1997)) tested a synthetic peptide, CP-11, Ile-Leu-Lys-Lys-Trp-Pro-Trp-Trp-Pro-Trp-Arg-Arg, based on indolicidin, which was designed to increase the number of positively charged residues, maintain the short length (13 amino acids), and enhance the amphipathicity relative to indolicidin. They found that CP-11 had better activity against *E. coli*, *Pseudomonas aeruginosa*, and *Candida albicans*, but reduced activity against *Staphylococcus aureus*. Lim et al. (J. Biochem. Mol. Biol. 30:229-33 (1997)) tested the effects of substituting certain tryptophan, proline or arginine residues in indolicidin. Substitutions of some tryptophan residues by isoleucine or glycine were tolerated but substitution of Pro⁷ with alanine significantly reduced activity against *E. coli*. Substitutions of either Arg¹² or Arg¹³ with alanine also reduced biological activity.

SUMMARY OF THE INVENTION

Applicants have discovered that indolicidin exhibits remarkable resistance to proteolysis by proteases. Applicants have also discovered that Rev4, the reverse peptide of indolicidin, and derivatives and analogs of indolicidin and Rev4 share these properties while maintaining antimicrobial properties. Applicants have further discovered that exogenous or non-native peptides, polypeptides and proteins of agronomic interest (hereinafter "proteins of agronomic interest") exhibit greater resistance to degradation by multiple classes of proteases that have different active sites and substrate specificities in the presence of indolicidin, Rev4 and related structures.

One aspect of the present invention is directed to an isolated and purified peptide which is, includes, or consists essentially of Rev4, or a functional equivalent thereof that exhibits antimicrobial properties and/or renders other proteins applied to and/or produced by plants more resistant to proteolytic degradation. This aspect of the

present invention also entails nucleic acids including or consisting essentially of sequences encoding Rev4, and nucleic acid constructs such as vectors containing the Rev4-encoding sequence. Recombinant cells such as plants and bacteria (e.g., *Agrobacterium tumefaciens*) and protoplast containing the Rev4-encoding sequence are also entailed. Transgenic plants that express Rev4-encoding nucleic acids exhibit increased resistance to microbial pathogens that infect plants. Transgenic plants can be made in accordance with standard techniques including regenerating plants from transformed protoplasts or transformed plant tissue. Yet another embodiment of this aspect of the invention relates to seeds derived from the transgenic plants. In yet another embodiment, increased resistance to microbial infection may be imparted to a given plant species by applying to the plant a composition containing the Rev4 protein or functional equivalent thereof. These compositions may be in the form of a dry powder or a liquid dispersion suitable for spraying, etc.

Another aspect of the present invention is directed to a method of decreasing the extent of or inhibiting proteolytic degradation of a non-native protein susceptible to proteolytic degradation, on or in a plant. The method entails administering to a plant indolicidin, Rev4 or a functional equivalent thereof, before simultaneously with, or after the administration of a non-native protein of interest, such as an anti-pathogenic protein. The "administration" of the Rev4 or indolicidin as in the case of the Rev4-containing compositions, above, may be accomplished by direct application to the plant or by genetic engineering techniques whereby a transgenic plant is produced. In the case of transgenics, the non-native construct containing the Rev4 or indolicidin may be constructed so as to be expressed before, during or suitably after expression of the non-native DNA encoding the non-native protein of interest. This method may also be described in terms of a method of preserving or increasing the activity of a given non-native protein applied to or produced by a plant, the non-native protein being susceptible to proteolytic

degradation. In preferred embodiments, transgenic plants contain recombinant nucleic acid molecules containing a first sequence encoding Rev4, indolicidin, or a functional equivalent thereof, and a second sequence encoding the protein of interest.

One aspect of the present invention is directed to synthetic peptides comprising Rev4 having the amino acid sequence Arg-Arg-Trp-Pro-Trp-Trp-Pro-Trp-Lys-Trp-Pro-Leu-Ile ("Rev4"), and analogs and derivatives of Rev4 that exhibit antimicrobial and anti-proteolytic properties, nucleic acids encoding these peptides, as well as nucleic acid constructs, vectors and hosts containing the nucleic acids are also disclosed.

Another aspect of the present invention provides a method for increasing resistance of peptides, polypeptides and proteins of agronomic interest to degradation or inactivation by proteases or reducing the extent of protease degradation. In preferred embodiments, DNAs encoding the peptides of the present invention are co-expressed with another non-native nucleic acid encoding an antifungal, antibacterial, antiviral and insecticidal protein, or any other preferred proteins of interest are beneficial to the plant and/or impart resistance to plant disease and pathogens.

The present invention also provides nucleic acids and genetic constructs comprising sequences that encode Rev4 and biologically functional equivalents thereof, and methods for inserting such nucleic acid sequences and genetic constructs into host cells for the production of the peptides encoded thereby.

Transgenic plants, parts or cells thereof, and seed derived from the plants are also included.

The present invention also provides recombinant microorganisms and protoplasts containing nucleic acid sequences that encode the peptides according to the present invention.

The present invention also provides antipathogenic compositions, comprising at least one of the peptides of the present invention along with at least one antifungal,

antibacterial, antiviral or insecticidal agent.

The compositions of the present invention also include recombinant host cells, such as bacterial (e.g., *agrobacterium tumefaciens*) and fungal cells, which produce the peptides of the present invention and at least one antipathogenic protein. In preferred embodiments, the compositions are applied to roots and/or leaves. The cells colonize the roots and/or leaves of plants.

DESCRIPTION OF THE FIGURES

10 Fig. 1 is gene construct RIL which includes a nucleic acid sequence encoding Rev4

Fig. 2 is graph depicting the stability of Rev4 and related structures to proteolysis.

15 Fig. 3 is graph depicting bacterial pathogen resistance of transgenic plants containing Rev4.

DETAILED DESCRIPTION OF THE INVENTION

The contents of each of the publications discussed in this specification, including the references cited therein, are herein incorporated by reference in their entirety.

20 The phrase "functional equivalent peptide" is meant to include peptide, polypeptide, and protein derivatives and analogs of indolicidin and Rev4 that exhibit sequence similarity to indolicidin and Rev4, and which exhibit the same or similar antimicrobial activity and/or ability to increase the resistance of other proteins to degradation or
25 inactivation by proteases. These properties may be determined by the methods described in Examples 7-13 of the specification.

30 Functional equivalent peptides also include amino acid sequences containing conservative amino acid changes in the sequence. In such amino acid sequences, one or more amino acids in the fundamental sequence is substituted with another amino acid or amino acids, the charge and polarity of which is similar to that of the native amino acid, i.e., a conservative
35 amino acid substitution resulting in a silent change. The amino acids may include any of the D-amino acids corresponding to the 20 L-amino acids commonly found in proteins, imino

amino acids, rare amino acids, such as hydroxylysine, or non-protein amino acids, such as homoserine and ornithine. A peptide may have none, one, or more of these derivatives and D-amino acids.

5 Substitutions, additions, deletions and non-naturally occurring derivatives of amino acid residues are also within the scope of functional equivalent peptides of present invention.

10 Amino acid substitutions within the fundamental polypeptide sequences are preferably selected from other members of the class to which the naturally occurring amino acid belongs. See Table 1. Amino acids are typically be divided into the following four groups: (1) acidic amino acids; (2) basic amino acids; (3) neutral polar amino acids; 15 and (4) neutral non-polar amino acids. Conservative amino acid changes within the fundamental polypeptide sequence are made by substituting one amino acid within the same group.

TABLE 1: PREFERRED AMINO ACID SUBSTITUTIONS

| Arg | Trp | Pro | Lys | Leu | Ile |
|-----|-----|-----|-----|-----|-----|
| Lys | Gly | Trp | Arg | Pro | Pro |
| His | Ala | Glu | His | Trp | Trp |
| | Val | Ala | | Gly | Gly |
| | Leu | Val | | Ala | Ala |
| | Ile | Leu | | Val | Val |
| | Pro | Ile | | Ile | Leu |
| | Phe | Phe | | Phe | Phe |
| | Met | Met | | Met | Met |
| | Lys | Lys | | Lys | Lys |

20 Preferred equivalents of indolicidin and Rev4 are represented by the following sequences:

- (1) Y-Y-Y-Y-X-Y-Y-Y-Y-X-X
- (2) X-X-Y-Y-Y-Y-X-Y-Y-Y-Y

25 wherein each X is independently arginine, lysine or histidine and each Y is independently tryptophan, glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, or lysine.

In other preferred embodiments, the functional

equivalent proteins contemplated herein possess about 70% or greater sequence similarity, more preferably about 80% or greater sequence similarity, and most preferably about 90% or greater sequence similarity.

5 The modification of any of the peptide residues in the sequence, including the N- or C-terminal residues, is also within the scope of this invention. The peptides may be altered by chemical or biological means, such as, for example, methylation and amidation, and alteration of amino acid sides
10 chain, such as acylation. The peptides may also be labeled, such as with a radioactive label, a fluorescent label, a mass spectrometry tag, biotin and the like. The peptides may also include additions of amino acids to the N- and C-termini. For example, a glycine residue may be added to the C-terminus to
15 provide a precursor for C-terminal amidation. See Bradbury, A.F. and Smyth, D.G., 1991, TIBS 16:112.

The peptides may also be conjugated, fused, or crosslinked to the protein of interest. Examples of include Ser-Rev4-OH comprising the amino acid sequence Ser-Arg-Arg-
20 Trp-Pro-Trp-Trp-Pro-Trp-Lys-Trp-Pro-Leu-Ile and Rev4-C-fusion comprising the amino acid sequence Arg-Arg-Trp-Pro-Trp-Trp-Pro-Trp-Lys-Trp-Pro-Leu-Ile-Gly-Gly-Gly-Tyr-Asp-Pro-Ala-Pro-Pro-Pro-Pro-Pro.

The peptides of the present invention may be
25 synthesized in accordance with standard techniques, including, but not limited to, chemical synthesis, synthesis by automated procedure, synthesis in heterologous biological systems such as microbial, plant and animal systems, tissue cultures, cell cultures, or in vitro translation systems. For example, the
30 peptides may be synthesized using standard solid-phase Fmoc protection strategy with HATU as the coupling agent. Other synthesis techniques include the t-Boc protection strategy and the use of different coupling reagents.

The present invention also includes nucleic acid
35 sequences comprising or consisting essentially of sequences that encode peptides of the present invention. Nucleic acid sequences include DNA, RNA, genomic DNA, mitochondrial DNA, chloroplast DNA, plasmid DNA, cDNA, synthetic DNA, and mRNA

nucleotide sequences.

The present invention also comprises nucleic acid constructs comprising the nucleic acids of the present invention and methods for inserting such nucleic acids into host cells. Preferably, the nucleic acid constructs contain a promoter sequence and a sequence encoding Rev4 or a functional equivalent thereof. The nucleic acid sequences can be inserted into a variety of host systems suitable for production of the peptide, including, for example, microorganisms, fungi and plants. Examples of promoters suitable for use in the present invention include broad expression promoters such as CaMV and Brassica ALS3, tissue/cell-type specific promoters such as the maize ZRP2; pathogen induced promoters such as HMG2 and tobacco hsr203J; pest/wound inducible promoters such as potato pin II, potato wun 1, and poplar Win6; stress inducible promoters such as *Arabidopsis rd29A* and *Arabidopsis adh*; and chemically induced promoters such as wheat Em, soybean GH3, and potato CDI.

Other regulatory sequences may also be included in the construct. Such sequences include, without limitation, an enhancer, repressor, ribosome binding site, transcription termination signal sequence, secretion signal sequence, origin of replication, selectable marker, and the like. The regulatory sequences are operationally associated with one another to allow transcription and subsequent translation.

Reporter genes may also be included in the construct in order to monitor transcription and translation. In preferred embodiments, the nucleic acid sequence encoding Rev4 or a functional equivalent is introduced into a plant using an expression vector. Many expression vectors have been developed for the production of recombinant plants, including bacteria, plasmids and viruses. Plant viral vectors suitable for the present invention include, for example, those disclosed in U.S. Patent No. 5,316,931. The proteins and nucleic acids of the present invention are administered to a plant. Transgenic plants expressing Rev4 exhibit resistance to infection by microbial plant pathogens.

In another embodiment, transgenic plants produce

both indolicidin or Rev4 and another non-native protein. The transgenic plants are produced by preparing a plant having a genome that contains the DNA sequence encoding indolicidin, rev4 or functional equivalents thereof which are expressed. Preferably the transgenic plant is prepared by stably transforming a protoplast with the DNA sequence encoding indolicidin, rev4 or functional equivalents thereof. The transgenic plant may also be prepared by introducing and regenerating the plant from plant tissue containing the DNA molecule.

Preferably, the peptides of the present invention are co-expressed with antibacterial, antifungal, antiviral and/or insecticidal proteins, proteins of agronomic interest include proteins derived from *Bacillus thuringiensis* (B.t.), other *Bacillus* species, or *Photobacterium* or *Xenorhabdus* species; proteins involved in improving the quality of plant products or agronomic performance of plants, as well as peptides or proteins that are to be produced in plants for the purpose of extraction and use as pharmaceutical products, agricultural products, feed or food additives, industrial enzymes; peptides or proteins that cause an alteration in plant metabolism that leads to the production of metabolites that can be extracted and used as pharmaceutical products, feed and food additives, agricultural products such as fungicides or insecticides, and specialty chemicals or chemical intermediates that have commercial value.

In more preferred embodiments, the transgenic plants co-produce the indolicidin or Rev4 and Magainins, reverse Magainins, PGLc, reverse PGLc, PI's, reverse PI's, Cecropins, reverse Cecropins, Sarcotoxins, reverse Sarcotoxins, Bombinins, reverse Bombinins, XPFs, reverse XPF's, Thionins, reverse Thionins, Defensins, reverse Defensins, Melittins, reverse Melittins, PGL a, and reverse PGLa, Dermaseptins, reverse Dermaseptins, Histatins, reverse Histatins, peptides derived from pig myeloid cells, peptides derived from human neutrophil cathepsin G, antimicrobial peptides from bovine neutrophils, Seminalplasmin, antimicrobial derived from

Lactoferrin, Drosocin, Tachyplexins, reverse Tachyplexins, Maize Basic Peptide I, Tracheal antimicrobial peptides, Antimicrobial peptides from seeds of amaranth, antimicrobial peptides from seeds of Mirabilis jalapa, Ranalexin, Brevenin, 5 Subtilin, Nisin, Epidermin, Lactacin 481, and basic amphipathic peptides.

The co-production of a peptide that can protect a second protein from degradation or inactivation by proteases found in or on plants is advantageous in many different 10 situations. For example, if the second protein has antifungal, antibacterial, antiviral or insecticidal activity, but is susceptible to degradation or inactivation by plant proteases, the present invention enables the use of multiple antimicrobial proteins that exploit more than one mode of 15 action to protect plants against disease caused by pathogens.

This co-production thus reduces the possibility of developing resistant strains of pathogens, broaden the scope of plant disease resistance, and results in synergistic control of plant pathogens. If the second peptide, polypeptide or 20 protein is susceptible to degradation or inactivation by proteases endogenous to an invading plant pathogen, the use of the present invention may increase the range of pathogens against which a particular anti-pathogenic protein is active.

Thus, because of the remarkable stability of the peptides to 25 degradation or inactivation by the complex mixture of proteases present in whole cell extracts of plant tissues, the present invention may be particularly useful in maintaining antimicrobial activity in plant tissues that have been damaged by insects or post-harvest handling.

30 Similarly, potentially labile proteins may be protected from undue protease degradation or inactivation during extraction from plant tissues. If the second protein is insecticidal, the present invention provides a mechanism by which the insecticidal protein is stabilized against plant 35 proteases and that it accumulates to higher concentrations in healthy plant tissues and survive additional proteases, of plant or insect origin, encountered during insect feeding. For protection of feed, food and other products from spoilage

caused by insects or microorganisms, the indolicidin and Rev4 peptides do not have to be produced by a plant part that is a component of the feed, food or other product. The peptide may be added during post-harvesting processing and formulation.

5 Plants suitable for expression or application of the peptides disclosed in the present invention include flowering plants, and preferably, crop plants, e.g., monocots and dicots.

More preferred include maize, tomato, turfgrass, asparagus, papaya, sunflower, rye, beans, ginger, lotus, bamboo, potato,
10 rice, peanut, barley, malt, wheat, alfalfa, soybean, oat, eggplant, squash, onion, broccoli, sugarcane, sugar beet, beets, apples, oranges, grapefruit, pear, plum, peach, pineapple, grape, rose, carnation, daisy, tulip, Douglas fir, cedar, white pine, scotch pine, spruce, peas, cotton, flax,
15 coffee and tobacco.

The present invention also encompasses the use of nucleic acid sequences or constructs encoding indolicidin or Rev4 to produce recombinant vectors, for example, plasmids, recombinant microorganisms, probes, and primers useful in
20 identifying related nucleic acid sequences that encode peptides that confer resistance to plant disease and which confer stability to peptides, polypeptides, and proteins. The peptides may be synthesized by recombinant production using various host systems, including bacteria, yeast, insect, and
25 mammalian cells.

The present invention also provides antipathogenic compositions comprising indolicidin or Rev4 along with at least one other antifungal, antibacterial, antiviral or insecticidal protein. The compositions can be formulated by
30 conventional methods using any suitable carrier. Other ingredients such as inert materials, surfactants, solvents, and other additives, which are well known in the art, may be added to the compositions. The compositions may also be combined with fertilizers, insecticides, antifungal agents,
35 attractants, sterilizing agents, acaricides, nematodes, and herbicides.

Preferably, the indolicidin or Rev4 is applied in a

concentration in the range from about 1 µg/ml to about 50 µg/ml to obtain antimicrobial activity and in a concentration in the range of from about 1 µg/ml to about 100 µg/ml to protect other peptides, polypeptides, and proteins from protease degradation.

The compositions of the present invention also include those in the form of recombinant host cells, such as bacterial and fungal cells, that produce indolicidin or Rev4 and colonize roots and/or leaves of plants. The protease-inhibiting peptides of this invention can be used in various combinations with each other to obtain synergistic activity and/or to provide broader protection against multiple classes of proteases having different active sites and substrate specificity. For example, Rev4 may be combined with another peptide from the indolicidin/Rev4 family of protease-inhibiting peptide which exhibits increased activity in protecting a particular class of peptide, polypeptide or protein or which exhibits increased activity against a particular protease.

The detailed description of the invention has been provided to aid those skilled in the art in practicing the present invention. The detailed description should not be construed to unduly limit the present invention as modifications and variations in the embodiments discussed herein may be made by those of ordinary skill in the art without departing from the scope of the present discovery. The present invention can be better understood from the following illustrative, non-limiting examples.

EXAMPLE 1

Chemical Synthesis and Purification of Rev4 (amide)

Peptides of the type described in this invention can be synthesized and purified by standard techniques as discussed in detail in U.S. Patents Nos. 5,424,395 and 5,519,115. For convenience, they may also be purchased from one of many companies that offer custom peptide synthesis. One such company is Genosys Biotechnologies, Inc., P.O. Box 41027, Houston, TX 77240 (Tel: 281-363-3693). Synthesis of

the C-terminal amide form of Rev4 peptide (Arg Arg Trp Pro Trp Trp Pro Trp Lys Trp Pro Leu Ile) was contracted with Genosys Biotechnologies Inc. HPLC analysis using a VYDAC reverse phase C8 column eluted with a 10-90% gradient of acetonitrile over 34 minutes at a flow rate of 1.5 ml per minute showed the peptide to be greater than 95% pure with a single peak eluting after 24.548 minutes.

EXAMPLE 2

Chemical Synthesis and Purification of Indolicidin

Synthesis of the C-terminal amide form of indolicidin (Ile Leu Pro Trp Lys Trp Pro Trp Trp Pro Trp Arg Arg) was contracted with Genosys Biotechnologies Inc. HPLC analysis using a VYDAC reverse phase C8 column eluted with a 10-90% gradient of acetonitrile over 34 minutes at a flow rate of 1.5 ml per minute showed the peptide to be greater than 95% pure with a single peak eluting after 23.232 minutes.

EXAMPLE 3

Chemical Synthesis and Purification of Ser-Rev4

Synthesis of a non-C-terminal amide analog of Rev4 in which an extra Ser was added to the N-terminus (Ser Arg Arg Trp Pro Trp Trp Pro Trp Lys Trp Pro Leu Ile) was contracted with Genosys Biotechnologies Inc. HPLC analysis using a VYDAC reverse phase C8 column eluted with a 10-90% gradient of acetonitrile over 34 minutes at a flow rate of 1.5 ml per minute showed the peptide to be greater than 95% pure with a single peak eluting after 22.363 minutes.

EXAMPLE 4

Chemical Synthesis and Purification of Rev4-C-Terminal Fusion Peptide

Synthesis of a Rev4 with a C-terminal extension of 13 amino acids (Arg Arg Trp Pro Trp Trp Pro Trp Lys Trp Pro Leu Ile Gly Gly Gly Tyr Asp Pro Ala Pro Pro Pro Pro Pro) was contracted with Genosys Biotechnologies Inc. HPLC analysis using a VYDAC reverse phase C8 column eluted with a 10-90% gradient of acetonitrile over 34 minutes at a flow rate of 1.5 ml per minute showed the peptide to be greater than 95% pure with a single peak eluting after 21.213 minutes.

EXAMPLE 5

Chemical Synthesis and Purification of Indolicidin F (amide)

Synthesis of a C-amidated indolicidin in which the Trp residues were replaced with Phe (Ile Leu Pro Phe Lys Phe Pro Phe Phe Pro Phe Arg Arg) was contracted with Genosys Biotechnologies Inc. HPLC analysis using a VYDAC reverse phase C8 column eluted with a 10-90% gradient of acetonitrile over 34 minutes at a flow rate of 1.5 ml per minute showed the peptide to be greater than 95% pure with a single peak eluting after 20.415 minutes.

10 EXAMPLE 6

Chemical Synthesis and Purification of Indolicidin F-P (amide)

Synthesis of a C-amidated derivative of indolicidin in which the Trp residues were replaced by Phe and a Pro residue was deleted (Ile Leu Lys Gly Phe Pro Gly Phe Pro Arg Arg Lys) was contracted with Genosys Biotechnologies Inc. HPLC analysis using a VYDAC reverse phase C8 column eluted with a 10-90% gradient of acetonitrile over 34 minutes at a flow rate of 1.5 ml per minute showed the peptide to be greater than 95% pure with a single peak eluting after 15.527 minutes.

20 EXAMPLE 7

Stability of Reverse Peptides to Proteases Present in Plant Extracellular Fluid (ECF)

The stability of various reverse peptide versions of naturally occurring peptides was determined by incubating the reverse peptides with various dilutions of ECF and then measuring by HPLC analysis the percentage of parent peptide remaining at the end of the incubation period. See Fig. 2.

ECF was obtained from tobacco leaves in accordance with the method described in U.S. Patent No. 5,424,395. Fifty micrograms of each peptide was incubated with different amounts of ECF in 50 mM Tris-HCl buffer, pH 7.5, total volume 50 microliters, for one hour at 37° C. The reaction was stopped by adding 1% trifluoroacetic acid (TFA). A sample of the reaction mixture (20 μ L) was injected onto a Vydac C4 column (4.6x250 mm) in a Waters HPLC system with 515 pumps, 486 detector and Millennium software. The sample was eluted with a gradient of 0.1% TFA in water to 60% acetonitrile in

0.1% TFA. The area of the peak corresponding to the undigested peptide was integrated and compared with the equivalent peak from a 0% ECF control. The non-reverse peptide, MYP30 (Met Gly Ile Gly Lys Phe Leu Arg Glu Ala Gly Lys Phe Gly Lys Ala Phe Val Gly Glu Ile Met Lys Pro), was included as a reference. The ranking of peptide stabilities shown in Fig. 2 was Rev4 (reverse indolicidin; Arg Arg Trp Pro Trp Trp Pro Trp Lys Trp Pro Leu Ile)>Rev6 (reverse PGLc; Leu Ala Lys Leu Ala Val Lys Ala Ile Lys Gly Ala Ile Ala Gly Ala Lys Ser Ala Met Gly)> Rev3 (reverse cecropin P1; Arg Pro Gly Gly Gln Ile Ala Ile Ala Ile Gly Glu Ser Ile Arg Lys Lys Ala Ser Asn Glu Leu Lys Lys Ala Thr Lys Ser Leu Trp Ser)>MYP30 (Met Gly Ile Gly Lys Phe Leu Arg Glu Ala Gly Lys Phe Gly Lys Ala Phe Val Gly Glu Ile Met Lys Pro)>Rev2 (reverse cecropin amide; Lys Ala Ile Gln Thr Ala Gln Gly Val Val Ala Val Ala Pro Gly Ala Lys Ile Ile Gly Asp Arg Ile Asn Gln Gly Val Lys Glu Ile Lys Lys Phe Leu Lys Trp Lys)>Rev8 (reverse bobinin-like peptide; Asn Ala Phe His Glu Ala Leu Gly Lys Ala Leu Gly Lys Leu Ala Ser Lys Gly Ala Ser Leu Ile Ser Ala Gly Ile Gly).

20 EXAMPLE 8

Stability of Rev4 to Proteases Present in Whole Cell Extract (WCE)

Whole cell extract (WCE) was prepared by grinding one gram of Kentucky 14 tobacco leaf tissue in liquid nitrogen, followed by extraction with 3 mL of 100 mM Tris-HCl buffer, pH7.5, 50 mM NaCl. The mixture was clarified by spinning in a microcentrifuge (14,000 r.p.m., 5 minutes). The supernatant (WCE) was kept frozen as aliquots at -80° C until required for an assay. Fifty micrograms of each peptide was incubated with different amounts of WCE in 50 mM Tris-HCl buffer, pH 7.5, total volume 50 microliters, for one hour at 37° C. The reaction was stopped by adding 1% trifluoroacetic acid (TFA). A sample of the reaction mixture (20 µL) was injected onto a Vydac C4 column (4.6x250 mm) in a Waters HPLC system with 515 pumps, 486 detector and Millennium software. The sample was eluted with a gradient of 0.1% TFA in water to 60% acetonitrile in 0.1% TFA. The area of the peak corresponding to the undigested peptide was integrated and

compared with the equivalent peak from a 0% WCE control. MYP 30 (Met Gly Ile Gly Lys Phe Leu Arg Glu Ala Gly Lys Phe Gly Lys Ala Phe Val Gly Glu Ile Met Lys Pro) is more susceptible to degradation by WCE than ECF, but Rev4 (Arg Arg Trp Pro Trp Trp Pro Trp Lys Trp Pro Leu Ile) is much more stable to WCE than either MYP30 or Magainin 2 (Gly Ile Gly Lys Phe Leu His Ser Ala Lys Lys Phe Gly Lys Ala Phe Val Gly Glu Ile Met Asn Ser).

EXAMPLE 9

10 Ability of Rev4 to Protect Magainin 2 from Degradation by WCE

Assays for WCE protease degradation were performed as described in Example 8 except that one of the samples represented Magainin 2 that was mixed with Rev4 before the addition of WCE. The amounts of Magainin 2 and Rev4 remaining in the mixture were determined by HPLC as described for Examples 7 and 8. Rev4 was able to confer on Magainin 2 a stability to WCE equal to that of Rev4 itself (Table 2).

| % WCE | % Peptide Remaining Intact after 1 Hr. | | | |
|-------|--|-------|-------------------------------------|-------------------------------|
| | Magainin 2 | Rev 4 | Magainin 2 in Rev4 + Magainin 2 Mix | Rev4 in Magainin 2 + Rev4 Mix |
| 0 | 100 | 100 | 100 | 100 |
| 15 | 10.9 | 82.7 | 89.7 | 89.6 |
| 30 | 0.3 | 77.2 | 87.6 | 84.0 |
| 45 | 0.4 | 66.9 | ND | ND |
| 60 | 0.3 | 61.6 | 73.1 | 75.3 |
| 90 | 0.4 | 55.2 | 56.3 | 53.8 |

ND = not determined

EXAMPLE 10

20 Ability of Rev4 to Protect Proteins From Degradation by Commercial Protease

The ability of Rev4 to inhibit four different classes of proteases was tested using fluorescent labeled casein as substrate under the following conditions:

| Enzyme | Class | Enzyme Concentration (mg/mL) | Assay Buffer |
|--------|-------|------------------------------|--------------|
| | | | |

| | | | |
|------------------|----------------------|------|----------------------|
| Chymotrypsin | Serine Protease | 0.01 | 5 mM Tris-HCl, pH8.0 |
| Carboxypeptidase | Zinc Metalloprotease | 0.10 | 5 mM Tris-HCl, pH8.0 |
| Papain | Sulfhydryl Protease | 0.01 | 5 mM MES, pH6.2 |
| Pepsin | Acid Protease | 0.01 | 5 mM HCl, pH2.0 |

Each protease was incubated with substrate (5µg/mL fluorescent labeled casein; Molecular Probes Inc., Eugene, OR) and peptide in a total volume of 200 µL in a 96-well microtiter plate. Before use, papain was activated with cysteine (Arnon, 1970, Methods in Enzymology 19:226-44). After incubation at room temperature for one hour, fluorescence due to casein digestion was measured in a Luminescence Spectrometer (LS50B, Perkin Elmer Ltd., England) with an excitation wavelength of 505 nm and an emission wavelength of 513 nm. The blank control contained the substrate, buffer and peptide but lacked the protease. Under these conditions, Rev4 was found to inhibit chymotrypsin, carboxypeptidase and papain, but not pepsin (Table 3).

| Protease | % Inhibition of Proteolysis by Rev4 at Various Concentrations | | | | | | | |
|------------------|---|-----|----|-----|-----|----|----|-----|
| | (µg/ml) | | | | | | | |
| | 0 | 2.5 | 5 | 10 | 20 | 25 | 50 | 100 |
| Chymotrypsin | 0 | 16 | 42 | 75 | 97 | | | |
| Carboxypeptidase | 0 | 58 | 92 | 100 | 100 | | | |
| Papain | 0 | 29 | 72 | 93 | 99 | | | |
| Pepsin | 0 | | | | | 3 | 0 | 0 |

15 EXAMPLE 11

Antifungal Activity of Rev4

When subjected to blind testing by two independent research groups, Rev4 was identified to have broad spectrum activity against important plant pathogens including *Cercospora* spp., *Colletotrichum* spp., *Fusarium* spp. and

Helminthosporium spp.

Tobacco blue mold (*Peronospora tabacina*) was used to compare the antifungal activity of Rev4 with that of MYP30. Spores of *Peronospora tabacina* were harvested from infected tobacco leaf with sterile water and washed three times. The spore suspension was diluted to 2,000 spores per mL. Peptide solution (2 μ L) was added to spore suspension (48 μ L) in a 96-well microtiter plate. After incubation in the dark at room temperature for 24 hours, the number of germinated spores was determined microscopically. Rev4 was found to be significantly more potent than MYP30.

| Peptide | Concentration (μ g/mL) | Spore Germination (%) |
|---------|-----------------------------|-----------------------|
| MYP30 | 0 | 71 |
| | 1 | 60 |
| | 5 | 28 |
| | 25 | 10 |
| | 50 | 0 |
| Rev4 | 0 | 71 |
| | 1 | 46 |
| | 5 | 2 |
| | 25 | 0 |
| | 50 | 0 |

The antifungal activity of Rev4 and related peptides was also compared using two tomato pathogens, *Verticillium dahliae* race1 and *Alternaria alternata* f.sp. *lycopersici*.

Spores were harvested from pure cultures grown on V8 medium, diluted to 5,000 spores per mL, and tested against dilution series of peptides in 96-well plates as described in U.S. Patent No. 5,424,395. The minimum concentration required to completely inhibit spore germination for at least 48 hours was determined in triplicate:

| Peptide SEQ. ID No. | <i>Verticillium dahliae</i> | <i>Alternaria alternata</i> |
|---------------------|-----------------------------|-----------------------------|
| SEQ. ID No. 4 | 40 μ g/ml | 50 μ g/ml |
| SEQ. ID No. 5 | 50 μ g/ml | 100 μ g/ml |

| | | |
|---------------|---------------------|----------------------|
| SEQ. ID No. 6 | 23 $\mu\text{g/ml}$ | 50 $\mu\text{g/ml}$ |
| SEQ. ID No. 7 | 50 $\mu\text{g/ml}$ | 100 $\mu\text{g/ml}$ |
| | | |

EXAMPLE 12

Antifungal Activity of Rev4-Related Peptides

The peptides described as SEQ. ID Nos. 4,5,6,7 and 8 in Examples 1,3,4,5 and 6 were tested for antifungal activity as described in Example 11. All the Rev-related peptides showed significant inhibition of *Peronospora tabacina* spore germination when tested at a final concentration of 2 $\mu\text{g/mL}$.

| Peptide Treatment | % Germination (mean \pm sem) | % Control |
|-------------------------|--------------------------------|-----------|
| None (control) | 76.6 \pm 11.2 | 100 |
| SEQ. ID NO. 4 (Rev4) | 3.7 \pm 3.2 | 4 |
| SEQ. ID NO. 5 | 6.8 \pm 6.3 | 9 |
| SEQ. ID NO. 6 | 5.7 \pm 9.8 | 7 |
| SEQ. ID NO. 7 | 8.8 \pm 5.4 | 11 |
| SEQ. ID NO. 8 | 17.3 \pm 3.5 | 23 |

EXAMPLE 13

Ability of Rev4-Related Peptides to Protect a Protein Against Chymotrypsin

The peptides described in EXAMPLE 12 were tested for their effects on the action of chymotrypsin on casein using the methods described in EXAMPLE 10. Peptides related to Rev4 but comprising amino acid extensions on either the N-terminus (Ser Arg Arg Trp Pro Trp Trp Pro Trp Lys Trp Pro Leu Ile) or C-terminus (Arg Arg Trp Pro Trp Trp Pro Trp Lys Trp Pro Leu Ile Gly Gly Gly Tyr Asp Pro Ala Pro Pro Pro Pro Pro) protected fluorescent-labeled casein from the action of chymotrypsin. Peptides related to indolicidin (Ile Leu Pro Trp Lys Trp Pro Trp Trp Pro Trp Arg Arg) in which Trp residues were replaced by Phe (Ile Leu Pro Phe Lys Phe Pro Phe Phe Pro Phe Arg Arg; Ile Leu Lys Gly Phe Pro Gly Phe Pro Arg Arg Lys) did not have this protective effect, even though they had retained antifungal activity (EXAMPLE 12).

| Peptide Identity | Peptide | Chymotrypsin |
|------------------|---------|--------------|
|------------------|---------|--------------|

| | Concentration ($\mu\text{g/mL}$) | Activity (Fluorescence Units) | |
|----------------|---------------------------------------|-------------------------------------|-----------|
| | | Mean | +/-s.e.m. |
| None (control) | 0 | 375 | 58 |
| SEQ. ID NO. 5 | 5 | 162 | 25 |
| SEQ. ID NO. 5 | 20 | 44 | 18 |
| SEQ. ID NO. 6 | 5 | 212 | 22 |
| SEQ. ID NO. 6 | 20 | 45 | 6 |
| SEQ. ID NO. 7 | 5 | 386 | 71 |
| SEQ. ID NO. 7 | 20 | 385 | 13 |
| SEQ. ID NO. 8 | 5 | 385 | 85 |
| SEQ. ID NO. 8 | 20 | 321 | 68 |

EXAMPLE 14

Construction of a Gene ("RIL") Encoding Rev4 Peptide

A DNA sequence encoding Rev4 (Arg Arg Trp Pro Trp Trp Pro Trp Lys Trp Pro Leu Ile, no C-terminal amide) was designed according to the standard genetic codon and the tobacco codon usage table (found at web site <http://www.dna.affrc.go.jp>). Two oligonucleotide primers (AGGAGATGGCCTTGGTGGCCTTGAAATGGCCTCTTATT and CCAGTCTCTAGAACCAT GAGGAGATGGCCTTGG) were used to make the full coding sequence to clone into expression vectors. Full-length DNA was generated by polymerase chain reaction (PCR: Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual. Cold Spring Harbor Laboratory Press.). Taq DNA polymerase was purchased from Gibco BRL, and the reaction set up as suggested by the manufacturer. No template was needed for the PCR reaction because the two primers have overlapping regions (15 nucleotides). To facilitate the gene cloning, two restriction sites (XbaI and SacI) were engineered on both ends of the gene and extra nucleotides were added to the ends to ensure these enzyme digestions.

The digested PCR product was cloned into pBluescript II KS+ (or pBS, Stratagene, LaJolla, CA) plasmid vector with 5' AMV sequence in the multiple cloning site. The 5' AMV sequence, a translational enhancer from the 5' leader sequence of alfalfa mosaic virus (5' AMV; Jobling and Gehrke, 1987, Nature, 325:622-25), was used to enhance the translation of the mRNA. The RIL gene coding sequence was inserted into the vector behind this 5' AMV sequence (see Fig. 1). This

construct, 5' AMV-RIL, was excised by digestion with XhoI and SacI and inserted into a binary vector pKLP36 (Maiti and Shepherd, 1998, Biochem. Biophys. Res. Comm. 244:440-44), yielding a construct named pKLP RIL. The pKLP36 vector contains the transfer DNA (T-DNA) right and left borders for gene insertion into plant genomes, a NPTII gene (for Kanamycin resistance) as a selectable marker for plant transformation, and the 36S promoter from peanut chlorotic streak caulimovirus and the 3' untranslated sequence from a Rubisco small subunit gene (rbcS3', Fig. 1) to drive the expression of the assembled RIL gene.

EXAMPLE 15

Assembly of a PreRIL Gene for Secretion of Rev4 in Plants

A secretion signal peptide sequence from tobacco PR-1b (Cornelissen et al., 1986, EMBO J.5:34-40) was added to RIL to facilitate secretion of Rev4 into the extracellular space of plant tissues where invading pathogens might be first encountered. Two primers (GACTGGAGCTCTTAAATAAGAGGCCATTTCCAAGGCCACCAAGGCCATCTCCT and AGCTGGGAATTCTAGGAGATGGCCTTGGTGGC) were designed to introduce the signal sequence and preserve the native cleavage site for processing.

The PCR product (67 base pairs) was precipitated and digested with EcoRI and XbaI, then cloned into the pBS plasmid vector already containing the 5' AMV and PR-1b sequences to yield plasmid pBS PreRIL. The sequence identity was confirmed by DNA sequencing. The cassette 5'AMV-PR-1b-RIL was then excised with XhoI and XbaI and inserted into pKLP36 to create pKLPPreRIL.

EXAMPLE 16

Assembly of a Pro-Peptide PPRIL Gene Encoding Rev4 Peptide

Natural peptide hormones are initially synthesized as large prepro-hormone precursors that are processed to form the smaller active peptides (Hook et al., 1994, FASEB J. 8:1269-78). Pro-sequences can facilitate the trans-membrane movement of peptides and prevent the release of active peptide until it is in the correct cellular compartment. In this

example we used a pro-sequence based on that found in natural magainin genes (Zasloff, 1987, PNAS 84:5449-53; ATGGACTCTAGATTAAATAAGAGGCCATTTCCAAGGCCACCAAGGCCATCTCCT) and linked it to Rev4-coding sequence through a His-Ser motif that corresponds to the site at which plant extracellular proteases cleave natural magainins (Everett, 1994, Chpt. 20 In: Natural and Engineered Pest Management Agents, eds. Hedin, Menn & Hollingworth, ACS Symposium Series 551, pp. 278-91). Correct processing at this site should leave an additional Ser residue on the N-terminus of Rev4, a modification that has been shown not to significantly reduce biological activity (Examples 12 and 13). Two oligonucleotide primers (AGCTGGGAATTCTAGGAGATGGCCTTGGTGGC and nucleic acid sequence corresponding to Leu-Pro-Gln-Pro-Glu-Ala-Ser-Ala-Asp-Glu-Gly-Val-Asp-Glu-Arg-Glu-Leu-His^x-Ser were used to generate the full-length gene by PCR as described above in previous Examples.

The PCR product was cloned into the pBS plasmid vector as in Example 15 to yield pBS PPRIL. As before, the gene cassette (5'AMV-PR-lb-Pro-RIL) was then inserted into pKLP36 as a XhoI/XbaI fragment and named pKLP PPRIL.

EXAMPLE 17

Assembly of PCRIL Gene Encoding Rev4 as a Fusion to a Fragment of PR-lb

The unusual amino acid composition and structure of Rev4 and related peptides might interfere with correct peptide secretion or processing if the Rev4 sequence is directly adjacent to the natural signal peptide processing site. This would be similar to the importance of both the transit peptide and the transported protein sequence for protein transport into chloroplasts (Wassman et al., 1986, Mol. Gen. Genet., 205:446-53). Accordingly, PCRIL was designed so that the Rev4 peptide would be fused to the C-terminus of a peptide corresponding to the first 20 amino acids of the PR-lb coding sequence, which naturally follows the PR-lb signal sequence. To facilitate release of Rev4 peptide from the PR-lb-Rev4 fusion product, the junction between PR-lb and Rev4 was engineered to include a cleavage site (Ala-Ala-Lys-Ile-) that

would be recognized by pepsin-like acid proteases that should not be inhibited by Rev4 (Example 10) and are produced by many fungi (Shintani et al., 1997, J. Biol. Chem. 272:18855-61, Morihara and Oka, 1973, Arch. Biochem. Biophys., 157:561-72).

5 The DNA encoding PR-lb signal peptide and the first 20 amino acids of the mature PR-lb protein was cloned by PCR from genomic DNA of *Nicotiana tabacum* cv Samsun NN using two oligonucleotide primers (AGCACTGAATTCTCTTCCACAACCAGA
GGCTTCTGCTGATGAAGGTGTTGATGAAAGAGAGCTCCATTCTAGGAGATGGCCTTGGTGG
10 and GTCACCTGCAGCCACGCCTACATCTGCAC). To be compatible with the cloning of the PR-lb protein coding sequence, the 5' cloning site of RIL was changed by a PCR reaction using CCAGTCTCTAGAACCATGAGGAGATGGCCTTGG and a new primer, ACGAAGCTTACCATGGGATTTTTTCTC. The cloned sequences were
15 verified by DNA sequencing. The DNA and amino acid sequences of this construct are listed in AGTCACTGCAGCTAAGATTAGGAGATGGCCTTGGTG and ATGGGATTTTTTCTCTTTTCACAAATGCCCTCATTTTTTCTTGTCTCTACACTTCTCTTATT CCTAATAATATCTCACTCTTCTCATGCCCAAACCTCTCAACAAGACTATTTGGATGCCCATA
20 ACACAGCTCGTGCAGATGTAGGCGTGGCTGCAGCTAAGATTAGGAGATGGCCTTGGTGGCCT TGGAAATGGCCTCTTATTTAA, respectively. The gene cassette PCRIL as shown in Fig. 1 was first assembled in pBS and then moved into pKLP36, as described in previous Examples. The resulting new plasmid was pKLP PCRIL.

25 EXAMPLE 18

Assembly of pPZP AMY and pPZP APM

In order to test the protective activity of the Rev4 peptide on Myp30 *in vivo*, we have cloned the Myp30 gene into a second binary vector pPZP (Hajdukiewicz et al., 1994, Plant
30 Molecular Biology, 25:989-94) which contains the resistance gene of gentamycin as plant selection marker. This allows us to do a double transformation on the Rev4 containing plants with Myp30 gene as the second transformants can be selected as gentamycin resistance plants.

35 Myp30 (AMY) and PR-lb-Myp30 (APM) genes were excised as XhoI and SacI fragment from the pBS-AMY and pBS-APM constructs (Li et al., 1999, submitted for publication) and

ligated to promoter EMV-FLt-10 in the context of pKYLX (Maiti et al., 1997, Transgenic Research, 6:143-56). Then the promoter, AMY or APM with rbcS 3' UTR sequences were excised out by an EcoRI and ClaI (blunted), and ligated to pPZP221
5 vector (prepared as EcoRI and SmaI cutting), and the resulting plasmids named as pPZP-AMY and pPZP-APM, respectively.

EXAMPLE 19

Production of Polyclonal Antibodies against Rev4

The synthetic Rev4 peptide from Example 1 was
10 conjugated with keyhole limpet hemocyanin (Calbiochem, Inc.) following the procedure of Deen et al. (1990, J. Immunol. Methods 129:119-25). The conjugated and non-conjugated peptides were both injected into New Zealand rabbits as described by Ausubel et al. (1987, Current Protocols in
15 Molecular Biology. Wiley Interscience Press.) After four sets of injections, the sera were collected, 0.01% sodium azide was added, and the sera was stored at -80° C.

EXAMPLE 20

Production of Transgenic Plants Expressing Rev4 Gene 20 Constructs

The research described herein has identified a class of peptides, and their corresponding DNA sequences, that have enhanced stability against plant proteases and which may also stabilize other peptides, polypeptides or proteins against
25 degradation by proteases of plant, fungal, insect or other origins. Agronomic, horticultural, ornamental, and other economically or commercially useful plants can benefit from this invention by introducing these DNAs therein in a functionally operable manner so that they are expressed at a
30 level effective to confer on such transgenic plants improved disease resistance or some other improvement that is conferred by the expression of a peptide related to Rev4.

Because an important use of the invention is to use the introduction of a first gene encoding a Rev4-related
35 peptide to protect the peptide, polypeptide or protein product of a second gene against protease degradation, the second gene may already be present in the plant to be transformed; or the

first and second genes may be combined in one plant by sexual hybridization of two independent transformed plants, one containing the first gene and the other containing the second gene; or the two genes may be introduced simultaneously.

5 Furthermore, instead of the gene products of the first and second gene being produced from different transcriptional units that are provided with separate promoters and other gene expression components, the two peptides, polypeptides, or proteins may be produced from a single transcriptional unit
10 under the control of a single promoter. Such single transcriptional unit may represent a dicistronic unit in which the first and second gene sequences are separated by a DNA sequence which allows reinitiation of translation, or it may represent a single translational unit that produces a protein
15 fusion product that comprises the peptide, polypeptide or protein product of the first gene fused to the peptide, polypeptide or protein product of the second gene. Such fusion product may either retain the activity and function of the individual products of the first and second gene, or the
20 two individual products may be released from the fusion by a subsequent cleavage.

Transgenic plants that express biologically effective amounts of Rev4 and biologically functional equivalents thereof can be produced by:

25 (a) transforming plant cells with a recombinant DNA molecule comprising operatively linked in sequence in the 5' to 3' direction:

(i) a promoter region that directs the transcription of a gene in plants,

30 (ii) an optional DNA sequence which encodes a signal sequence that directs the sorting of proteins in the secretory system (see for example Chrispeels, 1991, Ann. Rev. Plant Physiol. Plant Mol. Biol. 42:21-53)

(iii) a DNA coding sequence that encodes an RNA
35 sequence which comprises a sequence which encodes Rev4 having essentially the same or similar biological properties as that of Rev4;

(iv) an optional DNA sequence which encodes a signal

sequence that directs the sorting of proteins in the secretory system (see for example Chrispeels, 1991, Ann. Rev. Plant Physiol. Plant Mol. Biol. 42:21-53)

5 (v) a 3' non-translated region that encodes a polyadenylation signal which functions in plant cells to cause transcriptional termination and the addition of polyadenylate nucleotides to the 3' end of said RNA sequence;

(b) selecting plant cells that have been transformed

10 (c) regenerating plant cells that have been transformed to produce differentiated, fertile, transgenic plants

(d) selecting a transformed plant, cells of which express said DNA coding sequence and produce a biologically functionally equivalent thereof.

15 Methods for transforming a wide variety of dicotyledonous and monocotyledonous plants are well documented in the literature (see for example U.S. Patent No. 5,773,696 and references therein). Such methods can be used by one ordinarily skilled in the art to produce transgenic plants
20 that express biologically effective amounts of a Rev4-related peptide or biologically functionally equivalent thereof.

By way of a non-limiting example, the introduction into tobacco of gene constructs which encode Rev4-related peptides is described. To enable the use of *Agrobacterium*-
25 mediated transformation, the pKLP constructs described in Examples 14, 15, 16, and 17 were transferred from *E. coli* to *Agrobacterium tumefaciens* C58 by a triparental mating procedure as described by Ditta et al. (1980, PNAS
77:7347-51).

30 The *Agrobacterium* containing RIL constructs were then used to transform tobacco (*Nicotiana tabacum* cv KY14) as described by Horsch et al. (1986, PNAS, 83:2571-75). Briefly, sterile leaf discs were co-cultured with the *Agrobacteria* on a non-selective medium (MS agar medium containing 3% sucrose and
35 2.5 mg/L benzylaminopurine, and 1 mg/L indole-3-acetic acid) for 2 days, followed by continued culture (transferred to

fresh medium once a week) on selection medium (same as non-selective one but containing 300 mg/L kanamycin (Sigma, St. Louis) and 500 mg/L mefoxin (Merck and Co., West Point, PA). When the regenerated, kanamycin-resistant plants were at the 3-4 leaf stage, they were transferred to rooting medium (MS agar medium containing 3% sucrose and 500 mg/L mefoxin) for root induction. Plantlets with roots were transplanted to soil and grown to maturity in a standard greenhouse.

The same set of *Agrobacteria* was used to transform *Arabidopsis thaliana* ecotype Columbia by a vacuum infiltration protocol (Bent et al., 1994, Science 265:1856-60). Briefly, flowering *Arabidopsis* plants were dipped into the *Agrobacteria* suspension, then vacuum was applied for 3 minutes. The seeds from the treated plants were harvested and screened on appropriate selection markers (kanamycin or gentamycin both in 50 mg/l). Double transformation of pKLP and pPZP constructs in *Arabidopsis* were generated by transforming pPZP containing *Agrobacteria* to already transformed pKLP RIL, PCRIL PPRIL and PrcRIL *Arabidopsis* plants.

EXAMPLE 21

Detection of Rev4 mRNA in Transgenic Plants

Because the level of expression of a transgene can vary considerably between different transformation events, it is useful to categorize transformants into high, medium, or low expressors in preparation for further analysis. Total RNA was isolated from the leaves of 7 to 8 week old transgenic plants using the RNAqueous phenol-free total RNA isolation kit (Ambion Inc., Austin, Texas). Equal amounts of total RNA (10 μ g) from individual transformants were separated on a 1.2% agarose gel, transferred to Nytran (Schleicher & Schell, Keene, NH), hybridized with a ³²P-labeled RIL DNA probe, and washed using standard protocols (Sambrook et al., 1989, Molecular Cloning, a Laboratory Manual. Cold Spring Harbor Laboratory Press.). The blots (not shown) were visualized by autoradiography and phosphor imager (Fujifilm Fluorescent Image Analyzer FLA-2000, Fuji, Japan).

EXAMPLE 22

Detection of Increased Bacterial Pathogen Resistance in Transgenic Plants

Leaf tissue (300 mg) was collected from leaves of
5 young plants (4-6 leaf stage) and homogenized in 200 μ L of 2x
SDS-PAGE sample buffer (0.125 M Tris HCl, pH 6.8, 20% [v/v]
glycerol, 2% [w/v] SDS, 10% [v/v] beta-mercaptoethanol, and
0.001% [w/v] bromophenol blue) using a mortar and pestle. The
10 samples were boiled for 10 minutes, centrifuged to pellet cell
debris, and the supernatant stored at -20° C for future
analysis.

For immunoblot analysis, the proteins from 30 mg of
leaf tissue were separated by 16.5% Tris-Tricine SDS-PAGE
(Schagger and Jagow, 1987, Anal. Biochem. 166:368-79, precast
15 gels from Bio-Rad Laboratories) and transferred to a
nitrocellulose membrane using a Trans Blot Cell (Bio-Rad
Laboratories) following the manufacturer's recommendations.
Filters were probed with polyclonal antibodies specific for
the Rev4 peptide (Example 18). Briefly, filters containing
20 transferred proteins were incubated at room temperature in
TTBS (20 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 0.05% [v/v] Tween
20, 3% [w/v] nonfat dried milk) for 30 minutes, followed by
incubation with the Rev-4 specific antibodies for 1 hour in
the same buffer. After the excess antibodies were removed
25 with four washes (5 minutes each) of TTBS, the filters were
incubated for 30 minutes with 3% milk-TTBS containing
peroxidase-conjugated goat antirabbit IgG (Jackson Immuno
Research Laboratories, Inc., West Grove, PA). The excess
second antibody was removed with four washes of TTBS and two
30 washes of water. Filters were then developed with
Chemiluminescence Reagent Plus Kit (DuPont NEN Research
Products, Boston, MA), and the resulting chemiluminescence
detected by exposure to photographic film.

The expression of RIL genes in transgenic plants can
35 also be detected using phenotypic analyses such as increased
disease resistance or any other convenient phenotype that
results from the biological properties of Rev4-related
peptides in combination with a second biologically active

peptide, polypeptide or protein.

EXAMPLE 23

Detection of Increased Bacterial Pathogen Resistance in Transgenic Plants

5 Increases in bacterial disease resistance can be performed in progeny of the primary transformants. A tobacco bacterial pathogen, *Erwinia carotovora* subsp. *carotovora* (Pirhonen et al., 1991, Molecular Plant-Microbe interactions, 4:276-83) was used for the testing of tobacco plants. The overnight culture of the bacteria was centrifuged (1,000 x g) and the pellet resuspended in sterile water until a solution with an OD₆₀₀-0.8 was obtained. Two μ l of the bacterial suspension were dropped onto an extended leaf of individual tobacco seedlings (5-6 weeks old) grown in a 24-well microtiter plate in MS medium. The tobacco seedlings were cultured in a growth chamber 23-24°C, with 10 hours light/14 hours dark period. Individual experiments consisted of 8 plants per replication and at least 6 replications for each transgenic line. After 14 days, the number of dead plants was recorded.

| Plant Line Code | % Plants Surviving <i>Erwinia carotovora</i> Test |
|-----------------|---|
| KYLX (Control) | 16 |
| RIL 26 | 48 |
| PCRIL 24 | 36 |
| PCRIL 26 | 61 |

Table *Erwinia carotovora* resistance tests of Rev4 transgenic tobacco plants. Two μ l of a bacterial suspension were inoculated onto the leaf of each tobacco seedling (4 weeks old), cultured in 24-well plates containing MS medium. Each test involved 8 replications of 6 plants for each transgenic line and the KYLX control.

For testing bacterial resistance of Rev4 transformed *Arabidopsis*, *Pseudomonas syringae* pv. *maculicola* ES4326 was used. An overnight culture of the bacteria was spun down and resuspended in 10 mM MgSO₄ with Silwet 1-77 (200 μ l/liter), to make OD₆₀₀-0.001. Four week-old *Arabidopsis* plants (grown at 8 hours light/16 hours dark, 23° C) were dipped in the bacterial solution, briefly drained and returned to the growth

chamber. After 4 days, pictures were taken and the average infected leaves in each group were grounded and spread on LB medium for bacteria counting.

EXAMPLE 24

5 Detection of Increased Fungal Pathogen Resistance in Transgenic Plants

Tobacco blue mold (*Peronospora tabacina*) was used to test transgenic tobacco plants for increased disease resistance to this fungal pathogen. Tobacco leaf panels (8
10 panels per leaf, one leaf per plant of the same age, and three plants of each line) were infiltrated with 100 spores in water solution (10 μ L). After 7 days, the total infected area on the individual leaves was measured. The reduction of the disease severity was calculated as percentage of that seen
15 with a water control.

For the fungal resistance of *Arabidopsis* Rev4 transgenic plants, *Peronospora parasitica* var. Noco 2 was used to the testing. The active spores of the fungus (in water, 50,000 spores/ml) was sprayed on the 2 week-old *Arabidopsis*
20 seedlings. After 6 days, the symptoms were recorded by photograph. The growth condition of the *Arabidopsis* plants were the same as in Example 22.

| PLANT LINE | AVERAGE NO. SPORES $\times 10^3/\text{cm}^2$ | STANDARD DEVIATION |
|---------------|---|--------------------|
| KIX (control) | 274 | 77 |
| ril 24 | 169 | 43 |
| pcril 24 | 169 | 65 |
| pcril 26 | 135 | 31 |

INDUSTRIAL APPLICABILITY

The invention relates to the agricultural industry.

SEQUENCE LISTING

SEQ. ID NO. 1 (24 amino acids) [MYP30]

Met Gly Ile Gly Lys Phe Leu Arg Glu Ala Gly Lys Phe
Gly Lys Ala Phe Val Gly Glu Ile Met Lys Pro

5 SEQ. ID NO. 2 (13 amino acids) [indolicidin (amide)]
Ile Leu Pro Trp Lys Trp Pro Trp Trp Pro Trp Arg Arg

SEQ. ID NO. 3 (13 amino acids) [CP-11]

Ile Leu Lys Lys Trp Pro Trp Trp Pro Trp Arg Arg Lys

SEQ. ID NO. 4 (13 amino acids) [Rev4 (amide)]

10 Arg Arg Trp Pro Trp Trp Pro Trp Lys Trp Pro Leu Ile

SEQ. ID NO. 5 (14 amino acids) [Ser-Rev4-OH]

Ser Arg Arg Trp Pro Trp Trp Pro Trp Lys Trp Pro Leu

Ile

SEQ. ID NO. 6 (26 amino acids) [Rev4-C-fusion]

15 Arg Arg Trp Pro Trp Trp Pro Trp Lys Trp Pro Leu Ile

Gly Gly Gly Tyr Asp Pro Ala Pro Pro Pro Pro Pro

SEQ. ID NO. 7 (13 amino acids) [Indolicidin F
(amide)]

Ile Leu Pro Phe Lys Phe Pro Phe Phe Pro Phe Arg Arg

20 SEQ. ID NO. 8 (12 amino acids) [Indolicidin F-P
(amide)]

Ile Leu Lys Gly Phe Pro Gly Phe Pro Arg Arg Lys

SEQ. ID NO. 9 (21 amino acids) [reverse PGLc]

Leu Ala Lys Leu Ala Val Lys Ala Ile Lys Gly Ala Ile

25 Ala Gly Ala Lys Ser Ala Met Gly

SEQ. ID NO. 10 (31 amino acids) [reverse cecropin
P1]

Arg Pro Gly Gly Gln Ile Ala Ile Ala Ile Gly Glu Ser

Ile Arg Lys Lys Ala Ser Asn Glu Leu Lys Lys Ala Thr Lys Ser

30 Leu Trp Ser

SEQ. ID NO. 11 (37 amino acids) [reverse cecropin A
amide]

Lys Ala Ile Gln Thr Ala Gln Gly Val Val Ala Val Ala

Pro Gly Ala Lys Ile Ile Gly Asp Arg Ile Asn Gln Gly Val Lys

35 Glu Ile Lys Lys Phe Leu Lys Trp Lys

SEQ. ID NO. 12 (27 amino acids) [reverse bombinin-
like peptide amide]

Asn Ala Phe His Glu Ala Leu Gly Lys Ala Leu Gly Lys

Leu Ala Ser Lys Gly Ala Ser Leu Ile Ser Ala Gly Ile Gly
 SEQ. ID NO. 13 (23 amino acids) [Magainin 2]
 Gly Ile Gly Lys Phe Leu His Ser Ala Lys Lys Phe Gly
 Lys Ala Phe Val Gly Glu Ile Met Asn Ser

5

SEQ. ID NO. 14 (RIL)

Arg-Arg-Trp-Pro-Trp-Trp-Pro-Trp-Lys-Trp-Pro-Leu-Ile

SEQ. ID NO. 15 (RIL Coding)

AGGAGATGGCCTTGGTGGCCTTGGAAATGGCCTCTTATT

SEQ. ID NO. 16 (primer RIL 5' XbaI)

10

CCAGTCTCTAGAACCATGAGGAGATGGCCTTGG

SEQ. ID NO. 17 (primer RIL 3' SacI)

GACTGGAGCTCTTAAATAAGAGGCCATTTCCAAGGCCACCAAGGCCATCTCC

T

SEQ. ID NO. 18 (primer RIL5' EcoRI)

15

AGCTGGGAATTCTAGGAGATGGCCTTGGTGGC

SEQ. ID NO. 19 (primer RIL 3' XbaI)

ATGGACTCTAGATTAAATAAGAGGCCATTTCCAAGGCCACCAAGGCCATCTC

CT

SEQ. ID NO. 20 (Pro)

20

Leu-Pro-Gln-Pro-Glu-Ala-Ser-Ala-Asp-Glu-Gly-Val-Asp-
 Glu-Arg-Glu-Leu- His*-Ser

SEQ. ID NO. 21 (primer PRIL 5')

AGCACTGAATTCTCTTCCACAACCAGAGGCTTCTGCTGATGAAGGTGTTGAT

GAAAGAGAGCTCCATTCTAGGAGATGGCCTTGGTGG

25

SEQ. ID NO. 22 (primer cPR1b 3' PstI)

GTCACCTGCAGCCACGCCTACATCTGCAC

SEQ. ID NO. 23 (primer PR-1b 5' HindIII/NcoI)

ACGAAGCTTACCATGGGATTTTTTCTC

SEQ. ID NO. 24 (primer RIL5' PstI)

30

AGTCACTGCAGCTAAGATTAGGAGATGGCCTTGGTG

SEQ. ID NO. 25 (PCRIL DNA coding sequence)

ATGGGATTTTTTCTCTTTTTCACAAATGCCCTCATTTTTTCTTGTCTCTACAC

TTCTCTTATTCCCTAATAATATCTCACTCTTCTCATGCCCAAACCTCTCAACAAGACTATTTG

GATGCCCATACACAGCTCGTGCAGATGTAGGCGTGGCTGCAGCTAAGATTAGGAGATGGCC

35

TTGGTGGCCTTGGAAATGGCCTCTTATTTAA

SEQ. ID NO. 26 (full sequence of PCRIL)

Met Gly Phe Phe Leu Phe Ser Gln Met Pro Ser Phe Phe
 Leu Val Ser Thr Leu Leu Leu Phe Leu Ile Ile Ser His Ser Ser

His Ala* Gln Asn Ser Gln Gln Asp Tyr Leu Asp Ala His Asn Thr
Ala Arg Ala Asp Val Gly Val Ala Ala Ala Lys#Ile Arg ArgTrp
Pro Trp Trp Pro Trp Lys Trp Pro Leu Ile

5 * and # are the PR-1b signal peptide and PR-1b
coding cleavage site, respectively. The RIL peptide sequence
is underlined.

We claim:

1. A method for reducing the extent of protease degradation of a protein applied to or produced by a plant comprising administering to the plant or a part thereof a peptide comprising indolicidin, Arg-Arg-Trp-Pro-Trp-Trp-Pro-Trp-Lys-Trp-Pro-Leu-Ile (Rev4) or a functional equivalent thereof.
2. The method of claim 1 wherein said functional equivalent comprises the formula:
- 10 X-X-Y-Y-Y-Y-Y-X-Y-Y-Y-Y; or
Y-Y-Y-Y-X-Y-Y-Y-Y-Y-Y-X-X
- wherein each X is independently arginine, lysine or histidine; and
- wherein each Y is independently tryptophan, glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, or lysine.
- 15 3. The method of claim 1 wherein said peptide is Ser-Arg-Arg-Trp-Pro-Trp-Trp-Pro-Trp-Lys-Trp-Pro-Leu-Ile (Ser-Rev4-OH).
- 20 4. The method of claim 1 wherein said peptide is Arg-Arg-Trp-Pro-Trp-Trp-Pro-Trp-Lys-Trp-Pro-Leu-Ile-Gly-Gly-Gly-Tyr-Asp-Pro-Ala-Pro-Pro-Pro-Pro-Pro (Rev4-C-Fusion).
5. The method of claim 1 wherein said protein is an antipathogenic agent.
- 25 6. The method of claim 5 wherein said protein is an antibacterial agent
7. The method of claim 5 wherein said protein is an antifungal agent.
8. The method of claim 5 wherein said protein is an antiviral agent.
- 30 9. The method of claim 5 wherein said protein is an insecticidal agent.
10. The method of claim 1 wherein said protein is selected from the group consisting of Magainins, reverse Magainins, PGLc, reverse PGLc, PI's, reverse PI's, Cecropins, reverse Cecropins, Sarcotoxins, reverse Sarcotoxins, Bombinins, reverse Bombinins, XPFs, reverse XPF's, Thionins, reverse Thionins, Defensins, reverse Defensins, Melittins,
- 35

reverse Melittins, PGL a, and reverse PGLa, Dermaseptins, reverse Dermaseptins, Histatins, reverse Histatins, peptides derived from pig myeloid cells, peptides derived from human neutrophil cathepsin G, antimicrobial peptides from bovine
5 neutrophils, Seminalplasmin, antimicrobial derived from Lactoferrin, Drosocin, Tachyplesins, reverse Tachyplesins, Maize Basic Peptide I, Tracheal antimicrobial peptides, Antimicrobial peptides from seeds of amaranth, antimicrobial peptides from seeds of Mirabilis jalapa, Ranalexin, Brevenin,
10 Subtilin, Nisin, Epidermin, Lactacin 481, and basic amphipathic peptides.

11. The method of claim 1 wherein said protein is selected from the group consisting of enzymes, pharmaceuticals, agricultural products, feed additives or food
15 additives.

12. The method of claim 1 wherein said peptide is Rev4 and said protein is selected from the group consisting of Magainins and reverse Magainins.

13. The method of claim 1 wherein said
20 administering comprises transforming said plant or part thereof with an non-native DNA comprising a sequence encoding said peptide.

14. The method of claim 1 wherein said
25 administering comprises spraying said plant or part thereof with a composition comprising said peptide functional equivalent.

15. The method of claim 14 wherein said composition further comprises said protein.

16. The method of claim 14 wherein said spraying
30 said plants or parts thereof is conducted after said plant or part thereof is harvested.

17. The method of claim 14 wherein said spraying said plants or parts thereof is conducted during processing or formulation of said plant or part thereof.

18. The method of claim 1 wherein said protease is
35 a plant protease.

19. The method of claim 1 wherein said protease is a bacterial protease.

20. The method of claim 1 wherein said protease is a viral protease.

21. The method of claim 1 wherein said protease is a fungal protease.

5 22. The method of claim 1 wherein said protease is an insect protease.

23. The method of claim 1 wherein said plant or part thereof is selected from the group consisting of maize, tomato, turfgrass, asparagus, papaya, sunflower, rye, beans, 10 ginger, lotus, bamboo, potato, rice, peanut, barley, malt, wheat, alfalfa, soybean, oat, eggplant, squash, onion, broccoli, sugarcane, sugar beet, beets, apples, oranges, grapefruit, pear, plum, peach, pineapple, grape, rose, carnation, daisy, tulip, Douglas fir, cedar, pine, spruce, 15 peas, cotton, flax, coffee and tobacco.

24. The method of claim 1 wherein said peptide is fused with at least one other peptide.

25. The method of claim 1 wherein said peptide is conjugated with at least one other peptide.

20 26. The method of claim 1 wherein said peptide is administered by applying said peptide to said plant or part thereof and said peptide is crosslinked with at least one other peptide.

27. A method of inhibiting the growth of a plant 25 pathogen comprising administering to a plant or part thereof Rev4 or a functional equivalent thereof.

28. A peptide comprising Rev4 (Arg-Arg-Trp-Pro-Trp-Trp-Pro-Trp-Lys-Trp-Pro-Leu-Ile) or a functional equivalent thereof.

30 29. A nucleic acid molecule comprising a sequence encoding Rev4 (Arg-Arg-Trp-Pro-Trp-Trp-Pro-Trp-Lys-Trp-Pro-Leu-Ile) or a functional equivalent thereof.

35 30. The nucleic acid molecule of claim 29 comprising AGGAGATGGCCTTGGTGGCCTTGAAATGGCCTCTTATT or a complement thereof.

31. The nucleic acid molecule of claim 29 which is DNA.

32. The nucleic acid segment of claim 29 which is

RNA.

33. A nucleic acid construct, comprising from 5' to 3', a transcriptional initiation region functional in plants, a nucleic acid sequence encoding Rev4 or a functional equivalent thereof, and a transcriptional termination sequence.

34. The nucleic acid construct of claim 33 further comprising a regulatory nucleic acid sequence.

35. The nucleic acid construct of claim 33 further comprising a reporter gene.

36. A transgenic plant comprising a nucleic acid including a sequence encoding Rev4 of a functional equivalent thereof.

37. The transgenic plant of claim 36 wherein said sequence encodes a functional equivalent or Rev4 comprising the formula:

X-X-Y-Y-Y-Y-Y-Y-X-Y-Y-Y-Y

wherein each X is independently arginine, lysine or histidine; and

wherein each Y is independently tryptophan, glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, or lysine.

38. The transgenic plant of claim 36 further comprising at least one nucleic acid sequence encoding a protein of agronomic interest.

39. A method of making a plant, comprising preparing a plant having a genome that contains a DNA sequence encoding Rev4 or a functional equivalent thereof wherein said sequence is expressed.

40. The method of claim 39 comprising stably transforming a protoplast with said DNA molecule, and generating the plant from the transformed protoplast.

41. The method of claim 39 comprising introducing the DNA molecule into plant tissue, and regenerating the plant tissue containing the DNA molecules.

42. The method of claim 39 wherein said plant further contains a DNA sequence encoding a protein of agronomic interest.

43. A seed derived from the plant of claim 36.

44. A plant cell comprising a nucleic acid sequence encoding Arg-Arg-Trp-Pro-Trp-Trp-Pro-Trp-Lys-Trp-Pro-Leu-Ile (Rev4) or a functional equivalent thereof.

5 45. The plant cell according to claim 44 further comprising a nucleic acid sequence encoding an agronomic protein of interest.

46. A composition for use in protecting a peptide, polypeptide or protein from protease degradation, comprising Rev4 or a functional equivalent thereof and a carrier.

10 47. The composition of claim 46 wherein said functional equivalent comprises the formula:

X-X-Y-Y-Y-Y-Y-X-Y-Y-Y-Y

15 wherein each X is independently arginine, lysine or histidine; and

wherein each Y is independently tryptophan, glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, or lysine.

20 48. The composition of claim 47 further comprising a protein of agronomic interest.

FIG. 1




FIG. 2





FIG. 3

| Lines | %surving plants |
|----------|-----------------|
| KYLX | 0.16 |
| RIL 26 | 0.48 |
| PCRIL 24 | 0.36 |
| PCRIL 26 | 0.61 |



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/25561

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :Please See Extra Sheet.

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 800/279, 288, 298, 301, 320, 320.1, 317, 313, 314, 315, 322; 435/129, 69.1, 69.2, 468, 419; 536/23.1, 24.1,

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------------|---|--|
| X ---- Y | US 5,519,115 A (MAPELLI ET AL) 21 May 1996 (21/5/96), see entire document, especially columns 3-4, 44-45, 62-63, 68-68, and 74-78. | 13, 29-39, 41-45 ----- 40 |
| Y | US 5,824,869 A (BROEKAERT ET AL) 20 October 1998 (20/10/98), columns 3-6, 14, and 25-26. | 13, 29-45 |
| X --- Y | US 5,424,395 A (BASCOMB ET AL) 13 June 1995(13/6/95), see entire document, especially columns 5-10, 35-39. | 1-2, 5-11, 14, 18, 23-28 ----- 3-4, 12, 15-17, 19-22 |

Further documents are listed in the continuation of Box C. See patent family annex.

| | |
|---|--|
| * Special categories of cited documents: | *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| *A* document defining the general state of the art which is not considered to be of particular relevance | *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| *E* earlier document published on or after the international filing date | *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | *&* document member of the same patent family |
| *O* document referring to an oral disclosure, use, exhibition or other means | |
| *P* document published prior to the international filing date but later than the priority date claimed | |

| | |
|---|--|
| Date of the actual completion of the international search 04 FEBRUARY 2000 | Date of mailing of the international search report 29 FEB 2000 |
|---|--|

| | |
|---|---|
| Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230 | Authorized officer MEDINA A. IBRAHIM Telephone No. (703) 308-0196 |
|---|---|

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/25561

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|---------------|--|---|
| Y,P | US 5,850,025 A (MIRKOV ET AL) 15 December 1998 (12/15/98), see entire document, especially columns 27-35. | 13, 29-45 |
| X --- Y | US 5,421,839 A (ULBRICH ET AL) 6 June 1995 (6/6/95), see entire document, especially columns 8-9. | 1-2, 7, 14, 18, 23, 27-28 ----- 3-6, 8-11, 16-17 |
| X,P | US 6,015, 941 A (RAO) 18 January 2000 (18/1/2000), see entire document, especially columns 1-5, 7-8. | 1-2, 24-27, 46-48 |
| Y | US 5,773,696 A (LIANG ET AL) 30 June 1998 (30/6/98), see entire document, especially columns 5, 7, lines 1-45, column 9, columns 13-14. | 1-2, 5-11, 14-18, 23-28, 46-48 |

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/25561

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/25561

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (7):

C12N 5/04, 15/05, 15/09, 15/31 15/63, 15/82; A01H 4/00, 3/04, 5/00, 5/10; C12P 21/02

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

800/279, 288, 298, 301, 320, 320.1, 317, 313, 314, 315, 322; 435/129, 69.1, 69.2, 468, 419; 536/23.1, 23.7, 24.1; 514/2; 530/300

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

DIALOG, WEST1.2a, STN CAS

TERMS: INDOLICIDIN, REV4, REVERSANT(s), ANTIBACTERIAL, ANTIGUNGAL, ANTIMICROBIAL, ANTIVIRAL, ANTIPATHOGEN-PEPTIDE, PROTEASE, PATHOGENIC RESISTANCE PLANTS

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-12, 14-28, 46-48, drawn to a method for reducing protease degradation of a protein applied to a plant comprising spraying a composition comprising indolicidin, Rev4, or a functional equivalent thereof.

Group II, claim(s) 13, 29-45, drawn to a method for reducing protease degradation of a protein produced by a plant comprising transforming the plant or plant part with a non-native DNA comprising a sequence coding indolicidin, Rev4 or functional equivalent thereof.

The inventions listed as Groups I and II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The claimed method for reducing a protease degradation of a protein applied to or produced by a plant comprising administering to the plant or plant part a peptide comprising a functional equivalent of Rev4 or indolicidin is anticipated by Ulbrich et al (US PAT# 5, 421,839), since the antifungal polypeptide taught by the reference would inherently contain a protease inhibiting activity.

The invention of Group I, drawn to a first method for reducing protease degradation of a protein applied to a plant, requires a composition comprising indolicidin or Rev4 peptide in the form of a dry powder or a liquid dispersion for direct application to the plant not required by Group II.

The invention of Group II, drawn to a second method for reducing protease degradation of a protein produced by a plant, requires an isolated nucleic acid encoding Rev4, regulatory sequences, and a plant transformation technique not required by Group I.